Category: 25813-24-5

Yi, Xiao; Chen, Jing; Xu, Xiuling; Ma, Yongmin published an article in 2017, the title of the article was Solvent and substituent effects on the conversion of 4-methoxypyridines to N-methyl-4-pyridones.Formula: C6H5Br2NO And the article contains the following content:

In the reaction of 4-methoxypyridine derivatives with alkyl iodides in the presence or absence of solvent, not only the pyridinium ions but also the related 1-methylpyridones are produced. The presence of solvent favors the formation of the 1-methylpyridone. Electron withdrawing groups on the pyridine ring also favor this conversion. A possible mechanism is presented. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to solvent substituent effect methoxypyridine derivative alkyl iodide pyridone, Physical Organic Chemistry: Addition, Elimination, and Substitution Reactions and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Safety of 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Safety of 3,5-Dibromo-4-methoxypyridine

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 7, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Application of 25813-24-5 The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Application of 25813-24-5

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Formula: C6H5Br2NO The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein R4 = independently H, halo, alkyl, (un)substituted NH2, etc.; A2 = substituted Ph, pyridyl, or pyrimidinyl; A5 = substituted heterocyclyl] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 2, 2012, Austin, Joel Francis; Sharma, Lisa S.; Balog, James Aaron; Huang, Audris; Velaparthi, Upender; Darne, Chetan Padmakar; Saulnier, Mark George published a patent.Category: pyridine-derivatives The title of the patent was Preparation of sulfonamide compounds useful as CYP17 inhibitors. And the patent contained the following:

The title compounds I [ring A = II-IV (wherein X, Y and Q = N and/or CR6; U = N, NR8, and/or CH; W and Z = N and/or C; with the provisos); R1 = H, halo, OH, etc.; R2 = H, halo, alkyl; R3 = H, halo, alkyl, alkoxy; R4 = H, halo, alkyl, alkoxy, haloalkoxy; R5 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; R6 = H, halo, CN, etc.; R7 = halo, CN, haloalkyl, etc.; R8 = H, alkyl, SO2Ph], useful in the treatment of conditions related to CYP17 enzyme, such as cancer, were prepared E.g., a multi-step synthesis of V, starting from 3-bromo-4-methylpyridine, was described. Exemplified compounds I showed human CYP17 SPA IC50 values of less than 1 μM (specific data given for representative compounds I). Pharmaceutical compositions comprising compound I were disclosed. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Category: pyridine-derivatives

The Article related to sulfonamide preparation cytochrome p450 monooxygenase cyp17 inhibitor antitumor, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Sulfenic, Sulfinic, and Sulfonic Acids and Derivatives and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu published a patent.Computed Properties of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders. And the patent contained the following:

The invention relates to coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof as novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2, R3, R4, X, and Y are as defined in the disclosure, are claimed. Example compounds such as II were prepared by multistep synthesis and evaluated in vitro and in vivo for their activity as CFTR correctors (data shown). Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis and chronic obstructive pulmonary diseases). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Computed Properties of 25813-24-5

The Article related to coumarin preparation cftr corrector chronic obstructive pulmonary disease treatment, Heterocyclic Compounds (One Hetero Atom): Benzopyrans (Including Coumarins, Isocoumarins, Chromones, Benzopyrones, Dibenzopyrans, and Other Arenopyrans) and other aspects.Computed Properties of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 11, 2016, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.Electric Literature of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Electric Literature of 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.SDS of cas: 25813-24-5 The title of the patent was Preparation of coumarin thiazolyl derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin thiazolyl derivatives I [R1 is H, halogen, OH, (un)substituted alkoxyl, (un)substituted amino, (un)substituted C1-6-alkyl, (un)substituted heterocycloalkyl; R2 is H, halogen, OH, NO2, CN, N3, thiocyanato, CF3, (un)substituted alkoxyl, (un)substituted amino, (un)substituted carbonyl, or (un)substituted C1-6-alkyl; R3 is H or substituted or unsubstituted C1-6-alkyl; R4 is (un)substituted C1-6-alkyl, (un)substituted aryl or (un)substituted heteroaryl; X is S or O; and, Y is O, NH or NMe] are provided. Thus, DBM-308 (II) was prepared from 3-chlorosalicylaldehyde via cyclocondensation with Et acetoacetate in EtOH containing piperidine to give 3-acetyl-8-chlorocoumarin (III); regioselective bromination with CuBr2 in CHCl3 to give 3-(bromoacetyl)-8-chlorocoumarin (IV); and cyclocondensation with 2-MeOC6H4NHC(:S)NH2 to give II. Methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The antiproliferative activity of II was determined [GI50 = 166 nM; TGI = 247 nM; LC50 = >4,000 nM; IC50 = 0.69 μM vs. N828 cell line (hyperproliferative PKD cells); IC50 = 0.54 μM vs. 3-8C1 cell line (hyperproliferative PKD cells)]. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).SDS of cas: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.SDS of cas: 25813-24-5 The title of the patent was Preparation of coumarin thiazolyl derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin thiazolyl derivatives I [R1 is H, halogen, OH, (un)substituted alkoxyl, (un)substituted amino, (un)substituted C1-6-alkyl, (un)substituted heterocycloalkyl; R2 is H, halogen, OH, NO2, CN, N3, thiocyanato, CF3, (un)substituted alkoxyl, (un)substituted amino, (un)substituted carbonyl, or (un)substituted C1-6-alkyl; R3 is H or substituted or unsubstituted C1-6-alkyl; R4 is (un)substituted C1-6-alkyl, (un)substituted aryl or (un)substituted heteroaryl; X is S or O; and, Y is O, NH or NMe] are provided. Thus, DBM-308 (II) was prepared from 3-chlorosalicylaldehyde via cyclocondensation with Et acetoacetate in EtOH containing piperidine to give 3-acetyl-8-chlorocoumarin (III); regioselective bromination with CuBr2 in CHCl3 to give 3-(bromoacetyl)-8-chlorocoumarin (IV); and cyclocondensation with 2-MeOC6H4NHC(:S)NH2 to give II. Methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The antiproliferative activity of II was determined [GI50 = 166 nM; TGI = 247 nM; LC50 = >4,000 nM; IC50 = 0.69 μM vs. N828 cell line (hyperproliferative PKD cells); IC50 = 0.54 μM vs. 3-8C1 cell line (hyperproliferative PKD cells)]. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).SDS of cas: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 11, 2016, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.Electric Literature of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Electric Literature of 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem